Speakers

Pasi Jänne, Mark Kris, Tony Mok, Suresh Ramalingam, Lecia Sequist

Pasi Jänne, MD, PhD

Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA

Dr. Jänne is a Translational Thoracic Medical Oncologist at the Dana Farber Cancer Institute and a Professor of Medicine at Harvard Medical School in Boston, MA. He is the Director of the Lowe Center for Thoracic Oncology and the Scientific Co-Director of the Belfer Institute for Applied Cancer Sciences also in Boston, MA. After earning his MD and PhD from the School of Medicine at the University of Pennsylvania in Philadelphia, PA, Dr. Jänne completed his internship and residency in Medicine at Brigham and Women’s Hospital in Boston, MA. He subsequently completed a fellowship training at the Dana Farber Cancer Instute/Massachusetts General Hospital combined program in Medical Oncology in 2001. In 2002, Dr. Jänne earned a Masters Degree in Clinical Investigation from Harvard University.

Dr Jänne’s research combines laboratory based studies, with translational research and clinical trials of novel therapeutic agents in patients with lung cancer. His main research interests center around understanding and translating the therapeutic importance of oncogenic alterations in lung cancer. Dr. Jänne has made seminal therapeutic discoveries, including being one of the co-discoverers of EGFR mutations, and findings from his work has led to the development of several clinical trials. In addition, he led the first-in man clinical trial of the mutant selective EGFR inhibitor osimertinib (AZD9291) which was recently approved by the Food and Drug Administration. Dr. Jänne has received several awards for his research including from Uniting Against Lung Cancer, American Lung Association, and the Bonnie J. Addario Lung Cancer Foundation. In 2008, he was elected as a member to the American Society of Clinical Investigation. Dr. Jänne is also the recipient of the 2010 American Association of Cancer Research (AACR) Richard and Hinda Rosenthal Memorial Award and a member of the 2010 AACR Team Science Award.

Back to top

Mark Kris, MD, FACP, FACCP

Attending Physician, Thoracic Oncology Service
The William and Joy Ruane Chair in Thoracic Oncology
Lead Physician, Memorial Sloan Kettering–IBM Watson Collaboration
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

Dr. Kris is an Attending Physician in the Thoracic Oncology Service at Memorial Hospital, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. He is the first incumbent of the William and Joy Ruane Chair in Thoracic Oncology. Dr. Kris is a Professor of Medicine at the Weill Cornell Medical College in New York, NY. Since 2012, he has served as the Lead Physician for the Memorial Sloan Kettering - IBM Watson Collaboration.

Dr. Kris graduated from Fordham University in Bronx, NY. After receiving his Medical Degree from Weill Cornell Medical College, he served as chief medical resident and fellow in Medical Oncology at Memorial Sloan Kettering Cancer Center.

Dr. Kris is author or coauthor of over 300 original scientific publications. He served as a member of the guideline panels on non-small cell lung cancers and antiemetics for the National Comprehensive Cancer Center Network from 1995-2015. Dr. Kris serves as Co-chair of the guideline panel for adjuvant chemotherapy and radiation for non-small cell lung cancers, and antiemetics for the American Society of Clinical Oncology. He is a Fellow of the American College of Physicians, The American College of Chest Physicians, and The American Society of Clinical Oncology. He received the first American Society of Clinical Oncology Humanitarian Award in 2011. Dr. Kris also received the Annie Blount Storrs Award from Calvary Hospital in 2014.

Dr. Kris is a specialist in lung cancers and other tumors arising in the chest. He is particularly interested in developing ways to choose treatments for patients based on molecular characteristics of their tumor specimens. His research also includes the evaluation of new anticancer agents (particularly those targeting lung cancers), multimodality therapy (using surgery, radiation and drugs together to improve outcomes for individuals with thoracic cancers), and the training of the IBM Watson cognitive computer to assist physicians and patients in choosing the best treatments.

Back to top

Tony Mok, BMSc, MD, FRCPC

Professor and Chair
Department of Clinical Oncology
The Chinese University of Hong Kong
Hong Kong, China

Dr. Mok was trained at the University of Alberta, Canada and he subsequently completed a fellowship in Medical Oncology at the Princess Margaret Hospital in Canada. After working as a community oncologist in Toronto, Canada for seven years, he returned to Hong Kong in 1996 to pursue an academic career.

Dr. Mok is Li Shu Fan Medical Foundation Named Professor of Clinical Oncology and Chairman of Clinical Oncology at The Chinese University of Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutation.

Dr. Mok has contributed to over 200 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is active and experienced in serving the academic societies. Dr. Mok is the past President of the International Association for the Study of Lung Cancer (IASLC), Past Chair of the American Society of Clinical Oncology (ASCO) International Affairs Committee, a member of the ASCO Publications Committee and Vice Secretary of the Chinese Society of Clinical Oncology (CSCO).

Dr. Mok is closely affiliated with the oncology community in China, and has received an Honorary Professorship at Guang Dong Province People’s Hospital, Guest Professorship at the Peking University, School of Oncology, Visiting Professorship at Shanghai Jiao Tong University, and West China School of Medicine/West China Hospital, Sichuan University. He is an Editor for thoracic oncology for the Journal of Clinical Oncology and has also authored eight books in Chinese and hosted three television series in Hong Kong.

Back to top

Suresh Ramalingam, MD

(Activity Chair)
Professor of Hematology and Medical Oncology
Director, Division of Medical Oncology
Assistant Dean for Cancer Research
Emory University School of Medicine
Deputy Director, Winship Cancer Institute
Atlanta, GA

Dr. Ramalingam is Professor of Hematology and Medical Oncology and the Assistant Dean for Cancer Research at the Emory University School of Medicine in Altanta, GA. He is also the Deputy Director of the Winship Cancer Institute of Emory University.

Dr. Ramalingam received his Medical Degree at Kilpauk Medical College in Madras, India. He completed his residency in Internal Medicine at Wayne State University in Detroit, MI, where he also served as Chief Medical Resident. He then completed a fellowship in Hematology and Medical Oncology at the University of Pittsburgh Medical Center in Pittsburgh, PA.

Dr. Ramalingam serves as the Chair of the ECOG-ACRIN Thoracic Malignancies Committee. He also serves on the Editorial Board of leading cancer journals such as the Journal of Clinical Oncology, Annals of Oncology, Cancer, Clinical Lung Cancer, and Translational Lung Cancer Research. Dr. Ramalingam is the recipient of several awards, including the James R. Eckman Award for Excellence in Teaching from the Department of Hematology and Medical Oncology, Emory University, and the Distinguished Cancer Scholar Award, Georgia Cancer Coalition. In addition, he is a recipient of the ASCO Career Development Award (2006–2009), the ECOG Young Investigator Award, and the NCI Clinical Investigators Team Leadership Award (2010-12). Dr. Ramalingam serves on several international, national, and institutional committees.

Dr. Ramalingam’s research interests include development of novel anti-cancer agents and evaluation of methods to individualize therapies for patients. He has conducted several clinical trials with molecularly targeted agents in the treatment of small cell and non-small cell lung cancer. Dr. Ramalingam has published more than 200 original manuscripts, review articles, editorials and book chapters.

Back to top

Lecia Sequist, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, MA

Dr. Sequist is originally from Michigan and studied chemistry at Cornell University in Ithaca, NY. She received her MD from Harvard Medical School in Boston, MA and trained in Internal Medicine at the Brigham and Women’s Hospital and in Hematology/Oncology at the Dana-Farber Cancer Institute, where she also received an MPH from the Harvard School of Public Health.

Dr. Sequist joined the faculty of the Center for Thoracic Cancers at the Massachusetts General Hospital Cancer Center in 2005 and has an active clinical and translational research career, as well as a busy practice caring for patients with lung cancer. She is currently an Associate Professor of Medicine at Harvard Medical School and the Mary B. Saltonstall Endowed Chair in Medical Oncology at Massachusetts General Hospital. Dr. Sequist has held grants from the National Institutes of Health (NIH), the Department of Defense (DOD), and many private foundations. Her research focuses on studying novel targets for lung cancer treatment, especially in patients with EGFR mutations and other driver oncogenes. Dr. Sequist also studies the changes that occur in cancers at the time of acquired drug resistance through tumor biopsies and non-invasive tests like CTC’s and ctDNA. She aims to develop personalized treatment algorithms for lung cancer, utilizing targeted therapies specific to the patients’ cancer genotypes, and understanding how this may change over the courses of the disease.

Back to top